Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?

The pace of scientific progress over the past several decades within the biological, drug development, and the digital realm has been remarkable. The’omics revolution has enabled a better understanding of the biological basis of disease, unlocking the possibility of new products such as gene and cel...

Full description

Bibliographic Details
Main Authors: Judith C. Macdonald, David C. Isom, Daniel D. Evans, Katy J. Page
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.660808/full
id doaj-7ac3403c8f564c1eb04b0741afe2f926
record_format Article
spelling doaj-7ac3403c8f564c1eb04b0741afe2f9262021-05-24T15:39:18ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-05-01810.3389/fmed.2021.660808660808Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?Judith C. Macdonald0David C. Isom1Daniel D. Evans2Katy J. Page3Global Regulatory Policy and Intelligence, Pfizer, Tadworth, United KingdomGlobal Regulatory Policy and Intelligence, Pfizer, Groton, CT, United StatesGlobal Biometrics and Data Management, Pfizer, Sandwich, United KingdomGlobal Regulatory Operations, Pfizer, Sandwich, United KingdomThe pace of scientific progress over the past several decades within the biological, drug development, and the digital realm has been remarkable. The’omics revolution has enabled a better understanding of the biological basis of disease, unlocking the possibility of new products such as gene and cell therapies which offer novel patient centric solutions. Innovative approaches to clinical trial designs promise greater efficiency, and in recent years, scientific collaborations, and consortia have been developing novel approaches to leverage new sources of evidence such as real-world data, patient experience data, and biomarker data. Alongside this there have been great strides in digital innovation. Cloud computing has become mainstream and the internet of things and blockchain technology have become a reality. These examples of transformation stand in sharp contrast to the current inefficient approach for regulatory submission, review, and approval of medicinal products. This process has not fundamentally changed since the beginning of medicine regulation in the late 1960s. Fortunately, progressive initiatives are emerging that will enrich and streamline regulatory decision making and deliver patient centric therapies, if they are successful in transforming the current transactional construct and harnessing scientific and technological advances. Such a radical transformation will not be simple for both regulatory authorities and company sponsors, nor will progress be linear. We examine the shortcomings of the current system with its entrenched and variable business processes, offer examples of progress as catalysts for change, and make the case for a new cloud based model. To optimize navigation toward this reality we identify implications and regulatory design questions which must be addressed. We conclude that a new model is possible and is slowly emerging through cumulative change initiatives that question, challenge, and redesign best practices, roles, and responsibilities, and that this must be combined with adaptation of behaviors and acquisition of new skills.https://www.frontiersin.org/articles/10.3389/fmed.2021.660808/fullregulatorydigitaldynamiccloudreviewartificial intelligence (AI)
collection DOAJ
language English
format Article
sources DOAJ
author Judith C. Macdonald
David C. Isom
Daniel D. Evans
Katy J. Page
spellingShingle Judith C. Macdonald
David C. Isom
Daniel D. Evans
Katy J. Page
Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
Frontiers in Medicine
regulatory
digital
dynamic
cloud
review
artificial intelligence (AI)
author_facet Judith C. Macdonald
David C. Isom
Daniel D. Evans
Katy J. Page
author_sort Judith C. Macdonald
title Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
title_short Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
title_full Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
title_fullStr Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
title_full_unstemmed Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
title_sort digital innovation in medicinal product regulatory submission, review, and approvals to create a dynamic regulatory ecosystem—are we ready for a revolution?
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-05-01
description The pace of scientific progress over the past several decades within the biological, drug development, and the digital realm has been remarkable. The’omics revolution has enabled a better understanding of the biological basis of disease, unlocking the possibility of new products such as gene and cell therapies which offer novel patient centric solutions. Innovative approaches to clinical trial designs promise greater efficiency, and in recent years, scientific collaborations, and consortia have been developing novel approaches to leverage new sources of evidence such as real-world data, patient experience data, and biomarker data. Alongside this there have been great strides in digital innovation. Cloud computing has become mainstream and the internet of things and blockchain technology have become a reality. These examples of transformation stand in sharp contrast to the current inefficient approach for regulatory submission, review, and approval of medicinal products. This process has not fundamentally changed since the beginning of medicine regulation in the late 1960s. Fortunately, progressive initiatives are emerging that will enrich and streamline regulatory decision making and deliver patient centric therapies, if they are successful in transforming the current transactional construct and harnessing scientific and technological advances. Such a radical transformation will not be simple for both regulatory authorities and company sponsors, nor will progress be linear. We examine the shortcomings of the current system with its entrenched and variable business processes, offer examples of progress as catalysts for change, and make the case for a new cloud based model. To optimize navigation toward this reality we identify implications and regulatory design questions which must be addressed. We conclude that a new model is possible and is slowly emerging through cumulative change initiatives that question, challenge, and redesign best practices, roles, and responsibilities, and that this must be combined with adaptation of behaviors and acquisition of new skills.
topic regulatory
digital
dynamic
cloud
review
artificial intelligence (AI)
url https://www.frontiersin.org/articles/10.3389/fmed.2021.660808/full
work_keys_str_mv AT judithcmacdonald digitalinnovationinmedicinalproductregulatorysubmissionreviewandapprovalstocreateadynamicregulatoryecosystemarewereadyforarevolution
AT davidcisom digitalinnovationinmedicinalproductregulatorysubmissionreviewandapprovalstocreateadynamicregulatoryecosystemarewereadyforarevolution
AT danieldevans digitalinnovationinmedicinalproductregulatorysubmissionreviewandapprovalstocreateadynamicregulatoryecosystemarewereadyforarevolution
AT katyjpage digitalinnovationinmedicinalproductregulatorysubmissionreviewandapprovalstocreateadynamicregulatoryecosystemarewereadyforarevolution
_version_ 1721428452131733504